ReviewBritish journal of clinical pharmacology2019
The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.
Review in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Effects of Benzodiazepines on Heart Failure Outcomes and Adverse Events: A Systematic Review and Meta-Analysis.Cardiovascular toxicology · 2026Pooled it
- Clinical Pharmacokinetics of Enalapril and Enalaprilat in Pediatric Patients-A Systematic Review.Frontiers in pediatrics · 2021Pooled it
- A randomized, cross-over trial of metoprolol succinate formulations to evaluate PK and PD end points for therapeutic equivalence.Clinical and translational science · 2022Trial
- Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure.Clinical pharmacokinetics · 2021Trial
- Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial.European journal of heart failure · 2020Trial
- Metformin Pharmacogenetics in Heart Failure Patients with Reduced Ejection Fraction: Impact on Metformin and Growth Differentiation Factor-15 Plasma Levels.Clinical pharmacokinetics · 2026Article
- Exploring the effects of renal and cardiac functions on the pharmacokinetics of vancomycin in patients undergoing cardiac surgery: a population pharmacokinetic analysis.International journal of clinical pharmacy · 2026Article
- Lidocaine-induced cardiac arrest during CT-guided lung biopsy: a case report of local anesthetic systemic toxicity outside the operating room.International journal of emergency medicine · 2026Article
- Clinical Pharmacology of Heart Failure in Frailty.European cardiology · 2026Review
- Pharmacokinetic Landscape and Interaction Potential of SGLT2 Inhibitors: Bridging In Vitro Findings and Clinical Implications.Pharmaceutics · 2025Review
- Echocardiographic hemodynamics correlate with differences in DOAC-specific bleeding and stroke rates in non-valvular atrial fibrillation.BMC cardiovascular disorders · 2025Article
- AI-Driven Innovation in Skin Kinetics for Transdermal Drug Delivery: Overcoming Barriers and Enhancing Precision.Pharmaceutics · 2025Review
- A Genome-Wide Association Study of Oxypurinol Concentrations in Patients Treated with Allopurinol.Journal of personalized medicine · 2024Article
- CBD and THC in Special Populations: Pharmacokinetics and Drug-Drug Interactions.Pharmaceutics · 2024Review
- Drug Related Problems among Older Inpatients at a Tertiary Care Setting.Journal of clinical medicine · 2024Article
- Review
- Recent Advancement of Medical Patch for Transdermal Drug Delivery.Medicina (Kaunas, Lithuania) · 2023Review
- Cardiac Hepatopathy: New Perspectives on Old Problems through a Prism of Endogenous Metabolic Regulations by Hepatokines.Antioxidants (Basel, Switzerland) · 2023Review
- Pharmacokinetic Alterations Associated with Critical Illness.Clinical pharmacokinetics · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prescribing in heart failure (HF), a common disease state that predominantly affects the older population, is often a challenging task because of the dynamic nature of the condition, requiring frequent monitoring and medication review, the presence of various comorbidities, and the frailty phenotype of many patients. The significant alterations in various organs and tissues occurring in HF, particularly the reduced cardiac output with peripheral hypoperfusion and the structural and functional changes of the gastrointestinal tract, liver and kidney, might affect the pharmacokinetics of several drugs. This review critically appraises the results of published studies investigating the pharmacokinetics of currently marketed cardiovascular and selected non-cardiovascular drugs in HF patients and control groups, identifies gaps in the current knowledge, and suggests avenues for future research in this complex patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.